Ten drugs were classified as low or no added therapeutic benefit compared with alternatives, accounting for $6.7 billion in ...

Meredith McKean, MD, MPH, discusses the background and goals from the recent long-term follow-up of a phase 1 study evaluating the combination of fianlimab and cemiplimab in advanced melanoma.

Senhwa Biosciences announces positive data from phase 1/expansion trial of Silmitasertib for basal cell carcinoma treatment: Taipei, Taiwan Thursday, April 3, 2025, 15:00 Hrs [IST ...

CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Response: Three patients achieved partial response (PR), while ten patients had stable ...

Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 ...

Sensei Biotherapeutics (SNSE) announced initial results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug, a ...

We recently published a list of 11 Best Extremely Profitable Stocks to Buy According to Analysts. In this article, we are ...

Avoid taking Vitamin D at night as it can disrupt the sleep hormone. Simultaneously, Vitamin D should be consumed with fatty foods for better absorption. Vitamin D is one of the most essential ...

We subsequently announced a clinical trial supply agreement with Regeneron for Libtayo in combination with IMM-1-104 in ... In December, the U.S. Food and Drug Administration (FDA) granted Fast Track ...

the FDA granted Orphan Drug designation to IMM-1-104 in the treatment of pancreatic cancer. Further IMM-1-104 Phase 2a data expected in the second quarter of 2025. Initiation of Phase 2a arm of ...